Parameter<\/th>	Value<\/th><\/tr>\n <\/thead>\n
Instrument<\/td>	Eli Lilly and Company (NYSE<\/a>: LLY)<\/td><\/tr>\n
Ticker in MobileTrader \/ MT5<\/td>	LLY<\/td><\/tr>\n
Idea Date<\/td>	August 25, 2026<\/td><\/tr>\n
Time Horizon<\/td>	1 to 3 months<\/td><\/tr>\n
Direction<\/td>	↑ Buy (Long)<\/td><\/tr>\n
Entry Level (trigger)<\/td>	1245.00 USD<\/td><\/tr>\n
Take Profit<\/a><\/td>	1400.00 USD<\/td><\/tr>\n
Stop Loss<\/a><\/td>	1139.00 USD<\/td><\/tr>\n
Risk per Trade<\/td>	No more than 3% of account · Medium risk<\/span><\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n \n \n \n Trade LLY Shares with RoboForex<\/div>\n Stocks<\/a>, indices<\/a>, metals, oil and currencies in one account, on mobile and on desktop.<\/div>\n <\/div>\n \n MobileTrader<\/a>\n MetaTrader 5<\/a>\n <\/div>\n <\/div>\n\n \n <\/span>Foundayo Reaches Its First European Market<\/span><\/h2>\n\n On 24 August, Eli Lilly started commercial sales<\/a> of Foundayo in the United Kingdom. The MHRA, the British medicines regulator, cleared the drug on 10 August for weight management and for the treatment of type 2 diabetes, and it has now reached patients.<\/p>\n\n At this first stage Foundayo is sold on private prescription only. Reaching the far larger public healthcare market requires an assessment by NICE, the body that decides which treatments the NHS pays for. Lilly is already working with the regulator, and the timing of a final decision is still open.<\/p>\n\n $\"Foundayo$ <\/a> Foundayo, the oral GLP-1 drug from Eli Lilly, is now on sale in the United Kingdom.<\/figcaption><\/figure>\n\n The British launch opens a long-term growth source for Eli Lilly. Even while sales run through private prescriptions, the company gets a real read on demand for a GLP-1 drug in tablet form. Inclusion in NHS programmes would widen the patient base considerably and speed up the sales curve.<\/p>\n\n The United Kingdom works as the first stage of a European expansion. A successful launch here, followed by wider access through the NHS, gives Lilly a case to take into other European markets and strengthens its position in the fast-growing segment of weight loss and diabetes treatments.<\/p>\n\n \n <\/span>What Foundayo Is and Where It Wins<\/span><\/h2>\n\n Foundayo is a GLP-1 class drug for weight loss and type 2 diabetes control. These are its main advantages over similar treatments already on the market:<\/p>\n\n \n Tablet form.<\/strong> Foundayo is taken once a day. Zepbound, Mounjaro and the injectable version of Wegovy all require regular injections.<\/li>\n Easier dosing.<\/strong> Oral Wegovy, the closest competitor, has to be taken on an empty stomach, and for at least 30 minutes afterwards the patient cannot eat, drink or take other oral medicines. Foundayo can be taken at any time of day, with food and water allowed.<\/li>\n Lower price.<\/strong> In the United Kingdom, Foundayo is expected to cost 100 to 120 GBP<\/a> per month, against roughly 330 GBP for a monthly course of Mounjaro injections. The lower price widens the pool of patients who can afford treatment.<\/li>\n Manufacturing scale.<\/strong> Foundayo is a small non-peptide molecule that needs no refrigerated storage or transport, which simplifies production and international distribution. Lilly set up several manufacturing sites and suppliers for the key production stages in advance. That matters in a market where a shortage of capacity has limited supply before.<\/li>\n <\/ul>\n\n On weight reduction alone, Foundayo still trails some of the injectable drugs. Its case rests on the combination of convenient dosing, a lower price and the ability to manufacture at scale.<\/p>\n\n \n <\/span>Foundayo Is Already Selling in the United States<\/span><\/h2>\n\n The United Kingdom is the first European market for Foundayo, and the United States came first overall. The FDA<\/a> approved the drug<\/a> on 1 April 2026, and commercial sales began on 9 April. Lilly distributes it through LillyDirect, telemedicine services and ordinary pharmacies, with a starting price of 149 USD per month for patients paying out of pocket.<\/p>\n\n The first full quarter of sales was small next to the company's main products. Foundayo revenue in Q2 2026 came to<\/a> 98 million USD, against 9.94 billion USD for Mounjaro and 4.93 billion USD for Zepbound.<\/p>\n\n A small opening quarter says little about where a GLP-1 drug ends up. Mounjaro also started modestly, at 187 million USD in Q3 2022, and reached quarterly revenue of 9.94 billion USD by Q2 2026. Zepbound started at 176 million USD in Q4 2023 and lifted quarterly sales to 4.93 billion USD in under three years. Both of Lilly's flagship drugs travelled from millions to billions of dollars per quarter.<\/p>\n\n $\"Eli$ <\/a> Quarterly revenue of Eli Lilly drugs since launch. Past results do not guarantee future performance.<\/figcaption><\/figure>\n\n Mounjaro and Zepbound together deliver almost 15 billion USD of quarterly sales and remain the engine of the company. Foundayo is a long way from that scale today. What the market is pricing at this stage is the trajectory: if the new pill repeats even part of the path the other two took, 98 million USD becomes the starting point of a much larger business.<\/p>\n\n International expansion adds to the case, and it has only just started. There are early signals<\/a> worth watching. According to Investors Business Daily<\/a>, Foundayo prescriptions in the United States keep climbing quickly, and the growth rate of new prescriptions in recent weeks ran ahead of oral Wegovy.<\/p>\n\n \n <\/span>Eli Lilly Enters the Launch from a Position of Strength<\/span><\/h2>\n\n Foundayo arrives while the core business is growing at an unusual pace. In Q2 2026, Eli Lilly revenue rose 48% year on year to 22.97 billion USD, of which 14.87 billion USD came from Mounjaro and Zepbound. GAAP net income grew 25% to 7.10 billion USD, and adjusted earnings per share rose 33% to 8.38 USD.<\/p>\n\n Mounjaro sales outside the United States grew especially fast and reached 5.2 billion USD, which shows Lilly can scale a GLP-1 drug across international markets. After the quarter, management raised 2026 revenue guidance from a range of 82 to 85 billion USD to a range of 85 to 87 billion USD.<\/p>\n\n That gives Foundayo a comfortable starting position. Lilly can fund manufacturing, marketing and international promotion of the new pill out of the cash flow the existing line-up already generates, with no need for the launch to work immediately.<\/p>\n\n \n <\/span>LLY Analyst Ratings<\/span><\/h2>\n\n As of August 2026, Barchart analyst ratings<\/a> on Eli Lilly remain mostly positive. 26 of the 30 analysts covering the stock recommend buying it, and the remaining 4 say hold.<\/p>\n\n \n\n \n\n \n \n \n \n \n 26 out of 30<\/div>\n recommend Buy (86%)<\/div>\n <\/div>\n \n Hold<\/div> 4 (14%)<\/div><\/div>\n Sell<\/div> 0 (0%)<\/div><\/div>\n <\/div>\n \n Average Target Price<\/div>\n 1335.32 USD<\/div>\n <\/div>\n \n Maximum Target<\/div> 1600.00 USD<\/div><\/div>\n Minimum Target<\/div> 850.00 USD<\/div><\/div>\n <\/div>\n <\/div>\n\n <\/div>\n\n The average target price stands at 1335.32 USD, the highest at 1600.00 USD and the lowest at 850.00 USD. That spread shows a market that rates Lilly's prospects highly while staying careful about the current valuation and the dependence on further growth in GLP-1 sales.<\/p>\n\n \n <\/span>LLY Stock: the Technical Picture<\/span><\/h2>\n\n At the time of writing, LLY shares trade around 1245 USD.<\/p>\n\n On the daily chart the price holds above the 200-period Moving Average<\/a> and above the 20- and 50-period Moving Averages, which points to an uptrend that is still intact. At the same time the Stochastic<\/a> indicator sits close to overbought territory, so further gains are likely to come with local pullbacks along the way. The stock is in an advancing phase, so entry risk here is higher than it would be after a decline.<\/p>\n\n From that picture, the idea buys LLY at market price near 1245 USD. The target is 1400 USD, which lines up with the 161.80% Fibonacci level. The Stop Loss goes below support at 1140 USD, at the level of 1139 USD.<\/p>\n\n $\"Eli$ <\/a> Eli Lilly and Company (LLY) stock technical analysis and forecast, August 2026. Past results do not guarantee future performance.<\/figcaption><\/figure>\n\n \n The Moving Averages sit well below the current price,<\/strong> confirming the strength of the long-term uptrend.<\/li>\n Stochastic is near overbought territory,<\/strong> pointing to pullbacks on the way toward the 1400 USD target.<\/li>\n A market buy order<\/a><\/strong> is the best option here by risk and reward.<\/li>\n The 161.80% Fibonacci level at 1400 USD<\/strong> is the reference point for this idea.<\/li>\n <\/ul>\n\n Position management rule. Once the price has moved 8% in the direction of the forecast, the Stop Loss is moved up to the entry level. The protective order is then trailed behind the price at a distance of 8%. Management continues until the position closes at Take Profit or at Stop Loss, whichever the price reaches first.<\/p>\n\n \n <\/span>Sample Trading Strategy for LLY Shares<\/span><\/h2>\n\n Below is a sample trading strategy<\/a> for LLY shares. This example serves educational purposes only and does not constitute investment advice. Investors should assess their own risk tolerance independently.<\/p>\n\n \n \n \n \n Parameter<\/th> Value<\/th><\/tr>\n <\/thead>\n Entry Point<\/td> Buy at market price around 1245.00 USD<\/strong><\/span><\/td><\/tr>\n Take Profit<\/td> Fibonacci 161.80% at 1400.00 USD<\/strong><\/span><\/td><\/tr>\n Stop Loss<\/td> 1139.00 USD<\/strong>, just below support at 1140 USD<\/span><\/td><\/tr>\n Risk \/ Reward Ratio<\/td> 1 : 1.46, the potential profit is about 1.5 times the risk<\/span><\/td><\/tr>\n Position Size<\/td> No more than 3% of account<\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n Sample Calculation for 10 LLY Shares<\/h3>\n\n \n \n \n \n \n \n \n \n Scenario<\/th> Calculation<\/th> Result<\/th><\/tr>\n <\/thead>\n Buy 10 shares at 1245.00 USD<\/td>\n 10 × 1245.00 USD<\/td>\n 12,450 USD<\/td>\n <\/tr>\n If target reached (1400.00 USD)<\/td>\n (1400.00 − 1245.00) × 10<\/td>\n +1,550 USD (+12.4%)<\/td>\n <\/tr>\n If stop triggered (1139.00 USD)<\/td>\n (1245.00 − 1139.00) × 10<\/td>\n −1,060 USD (−8.5%)<\/td>\n <\/tr>\n Risk \/ Reward<\/strong><\/td>\n 1,060 \/ 1,550<\/td>\n 1 : 1.46<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n A risk\/reward ratio of 1 : 1.46 is moderate. The potential profit only modestly exceeds the risk taken, which leaves little room for a sloppy entry. Markets are volatile, and LLY shares can move both for and against an open position.<\/p>\n\n When This Idea Stops Being Valid<\/h3>\n\n The idea rests on the daily uptrend holding. It stops being valid in three cases, and each one has a clear signal:<\/p>\n\n \n A daily close below 1139 USD.<\/strong> That takes the price under the support at 1140 USD, breaks the structure the entry was built on and triggers the stop. The position closes at a loss of about 8.5% of its value.<\/li>\n A move above 1400 USD.<\/strong> The target is reached and the position closes in profit. Chasing the price beyond the Fibonacci 161.80% level is a different trade with different levels.<\/li>\n Three months pass with no target.<\/strong> The horizon for this idea is one to three months. If the price is still stuck between the stop and the target at the end of that window, the reason for holding has expired and the position is reviewed from scratch.<\/li>\n <\/ul>\n\n News can invalidate the idea before any of those levels arrive. A negative NICE decision on Foundayo, a fall in Foundayo prescriptions in the United States, or a Q3 report that misses on Mounjaro and Zepbound would all undercut the reasoning behind the entry, whatever the chart shows at that moment.<\/p>\n\n \n \n \n Open an Account and Trade US Stocks<\/div>\n Live charts, deposits and withdrawals, analytics and copy trading in one place.<\/div>\n <\/div>\n \n Open an Account<\/a>\n <\/div>\n <\/div>\n\n \n <\/span>Risks to Consider<\/span><\/h2>\n\n Strong financial results and the Foundayo rollout sit alongside several real risks in the LLY investment case.<\/p>\n\n \n High investor expectations.<\/strong> The shares have already risen a long way, so further gains depend on the company holding a very high growth rate.<\/li>\n Price pressure.<\/strong> In Q2 2026, Lilly's sales volume rose 60% while average realised prices fell 13%. Growth in patient numbers is arriving together with lower prices per treatment.<\/li>\n Competition from Novo Nordisk.<\/strong> Oral Wegovy still holds an advantage in the tablet segment, and the market keeps getting more competitive.<\/li>\n Limited access through public healthcare.<\/strong> Without positive decisions from regulators such as NICE, Foundayo may stay mainly a private prescription therapy.<\/li>\n Side effects of GLP-1 drugs.<\/strong> Foundayo shares the gastrointestinal side effects typical of its class, and those can lead patients to stop treatment.<\/li>\n Heavy dependence on diabetes and obesity drugs.<\/strong> Mounjaro and Zepbound together provide almost two thirds of company revenue, so any weakening of the GLP-1 market would show up quickly in Lilly's results.<\/li>\n <\/ul>\n\n The central risk is the level of expectation already priced in. Good results on their own may be read as a disappointment, and Lilly has to keep beating what the market assumes.<\/p>\n\n \n <\/span>Is Eli Lilly Stock Worth Buying on This News?<\/span><\/h2>\n\n The UK launch of Foundayo is a positive development for Eli Lilly shares, because it gives the market another potential source of multi-year revenue growth. The significance lies in the start of international scaling for a new GLP-1 drug. British sales themselves will have limited effect on the financial results of the coming quarters.<\/p>\n\n If Foundayo repeats even part of the Mounjaro and Zepbound trajectory, investors gain a reason to lift their expectations for future revenue and profit. That is the kind of shift that can drive a re-rating of LLY and support the share price from here.<\/p>\n\n The first quarter of Foundayo sales in the United States came to 98 million USD. Mounjaro and Zepbound also started with modest volumes and now bring in billions of dollars per quarter. A rising prescription count, a more accessible price and the opening of international markets create the conditions for similar scaling.<\/p>\n\n The strongest scenario for LLY combines continued growth in Mounjaro and Zepbound with accelerating Foundayo sales and entry into new markets. In that case the market can start pricing in a third multi-billion product. On the chart, the idea buys at market near 1245 USD, targets the Fibonacci 161.80% level at 1400 USD, and closes the position at 1139 USD if the support at 1140 USD gives way.<\/p>\n\n \n Open a Trading Account with RoboForex<\/a>\n <\/div>\n\n <\/span>FAQ<\/span><\/h2>\n\n \n \n What is Foundayo?<\/summary>\n Foundayo is Eli Lilly's oral GLP-1 drug for weight loss and type 2 diabetes control. It is taken once a day and does not require the food and water restrictions that come with oral Wegovy. It launched in the United States in April 2026 and in the United Kingdom in August 2026.<\/p>\n <\/details>\n \n Why does this trade idea target 1400 USD?<\/summary>\n 1400 USD lines up with the 161.80% Fibonacci extension of the recent uptrend, the level the technical picture points to from an entry near 1245 USD.<\/p>\n <\/details>\n \n What would invalidate this LLY trade idea?<\/summary>\n A daily close below 1139 USD, since that breaks the support the entry rests on and triggers the stop. A negative NICE decision on Foundayo or a weak Q3 report from Mounjaro and Zepbound would undercut the reasoning even before the chart reaches that level.<\/p>\n <\/details>\n \n Does the Foundayo launch mean LLY shares will reach the target?<\/summary>\n No. This is an educational trade idea built on the current technical and fundamental picture, not a promise of any specific price. LLY shares can move against the position, which is why the idea sets a stop-loss at 1139 USD.<\/p>\n <\/details>\n <\/div>\n\n \n * Any information provided in articles on this website is based solely on the personal opinions of the authors. These articles should not be construed as trading recommendations or a call to action. The authors and RoboForex accept no responsibility for the results of any trades made on the basis of these recommendations and reviews. Past performance is not indicative of future results. Trading stocks and CFDs involves a high risk of capital loss.<\/em>\n <\/div>\n\n<\/div>\n<\/div>\n\n\n\n\n\n

The idea buys at market near 1245 USD, targets 1400 USD and places the stop at 1139 USD.<\/li>\n <\/ul>\n <\/div>\n\n \n
<\/span>Trade Idea Parameters<\/span><\/h2>\n\n
Below are the parameters for the Eli Lilly trade idea. The ticker for trading via RoboForex MobileTrader<\/a> and MetaTrader 5<\/a> is LLY<\/strong>.<\/p>\n\n
\n \n \n \n
Parameter<\/th> Value<\/th><\/tr>\n <\/thead>\n
Instrument<\/td> Eli Lilly and Company (NYSE<\/a>: LLY)<\/td><\/tr>\n
Ticker in MobileTrader \/ MT5<\/td> LLY<\/td><\/tr>\n
Idea Date<\/td> August 25, 2026<\/td><\/tr>\n
Time Horizon<\/td> 1 to 3 months<\/td><\/tr>\n
Direction<\/td> ↑ Buy (Long)<\/td><\/tr>\n
Entry Level (trigger)<\/td> 1245.00 USD<\/td><\/tr>\n
Take Profit<\/a><\/td> 1400.00 USD<\/td><\/tr>\n
Stop Loss<\/a><\/td> 1139.00 USD<\/td><\/tr>\n
Risk per Trade<\/td> No more than 3% of account · Medium risk<\/span><\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n \n
\n
\n
Trade LLY Shares with RoboForex<\/div>\n
Stocks<\/a>, indices<\/a>, metals, oil and currencies in one account, on mobile and on desktop.<\/div>\n <\/div>\n
\n MobileTrader<\/a>\n MetaTrader 5<\/a>\n <\/div>\n <\/div>\n\n \n
<\/span>Foundayo Reaches Its First European Market<\/span><\/h2>\n\n
On 24 August, Eli Lilly started commercial sales<\/a> of Foundayo in the United Kingdom. The MHRA, the British medicines regulator, cleared the drug on 10 August for weight management and for the treatment of type 2 diabetes, and it has now reached patients.<\/p>\n\n
At this first stage Foundayo is sold on private prescription only. Reaching the far larger public healthcare market requires an assessment by NICE, the body that decides which treatments the NHS pays for. Lilly is already working with the regulator, and the timing of a final decision is still open.<\/p>\n\n
$\"Foundayo$ <\/a>
Foundayo, the oral GLP-1 drug from Eli Lilly, is now on sale in the United Kingdom.<\/figcaption><\/figure>\n\n
The British launch opens a long-term growth source for Eli Lilly. Even while sales run through private prescriptions, the company gets a real read on demand for a GLP-1 drug in tablet form. Inclusion in NHS programmes would widen the patient base considerably and speed up the sales curve.<\/p>\n\n
The United Kingdom works as the first stage of a European expansion. A successful launch here, followed by wider access through the NHS, gives Lilly a case to take into other European markets and strengthens its position in the fast-growing segment of weight loss and diabetes treatments.<\/p>\n\n \n
<\/span>What Foundayo Is and Where It Wins<\/span><\/h2>\n\n
Foundayo is a GLP-1 class drug for weight loss and type 2 diabetes control. These are its main advantages over similar treatments already on the market:<\/p>\n\n
\n
Tablet form.<\/strong> Foundayo is taken once a day. Zepbound, Mounjaro and the injectable version of Wegovy all require regular injections.<\/li>\n
Easier dosing.<\/strong> Oral Wegovy, the closest competitor, has to be taken on an empty stomach, and for at least 30 minutes afterwards the patient cannot eat, drink or take other oral medicines. Foundayo can be taken at any time of day, with food and water allowed.<\/li>\n
Lower price.<\/strong> In the United Kingdom, Foundayo is expected to cost 100 to 120 GBP<\/a> per month, against roughly 330 GBP for a monthly course of Mounjaro injections. The lower price widens the pool of patients who can afford treatment.<\/li>\n
Manufacturing scale.<\/strong> Foundayo is a small non-peptide molecule that needs no refrigerated storage or transport, which simplifies production and international distribution. Lilly set up several manufacturing sites and suppliers for the key production stages in advance. That matters in a market where a shortage of capacity has limited supply before.<\/li>\n <\/ul>\n\n
On weight reduction alone, Foundayo still trails some of the injectable drugs. Its case rests on the combination of convenient dosing, a lower price and the ability to manufacture at scale.<\/p>\n\n \n
<\/span>Foundayo Is Already Selling in the United States<\/span><\/h2>\n\n
The United Kingdom is the first European market for Foundayo, and the United States came first overall. The FDA<\/a> approved the drug<\/a> on 1 April 2026, and commercial sales began on 9 April. Lilly distributes it through LillyDirect, telemedicine services and ordinary pharmacies, with a starting price of 149 USD per month for patients paying out of pocket.<\/p>\n\n
The first full quarter of sales was small next to the company's main products. Foundayo revenue in Q2 2026 came to<\/a> 98 million USD, against 9.94 billion USD for Mounjaro and 4.93 billion USD for Zepbound.<\/p>\n\n
A small opening quarter says little about where a GLP-1 drug ends up. Mounjaro also started modestly, at 187 million USD in Q3 2022, and reached quarterly revenue of 9.94 billion USD by Q2 2026. Zepbound started at 176 million USD in Q4 2023 and lifted quarterly sales to 4.93 billion USD in under three years. Both of Lilly's flagship drugs travelled from millions to billions of dollars per quarter.<\/p>\n\n
$\"Eli$ <\/a>
Quarterly revenue of Eli Lilly drugs since launch. Past results do not guarantee future performance.<\/figcaption><\/figure>\n\n
Mounjaro and Zepbound together deliver almost 15 billion USD of quarterly sales and remain the engine of the company. Foundayo is a long way from that scale today. What the market is pricing at this stage is the trajectory: if the new pill repeats even part of the path the other two took, 98 million USD becomes the starting point of a much larger business.<\/p>\n\n
International expansion adds to the case, and it has only just started. There are early signals<\/a> worth watching. According to Investors Business Daily<\/a>, Foundayo prescriptions in the United States keep climbing quickly, and the growth rate of new prescriptions in recent weeks ran ahead of oral Wegovy.<\/p>\n\n \n
<\/span>Eli Lilly Enters the Launch from a Position of Strength<\/span><\/h2>\n\n
Foundayo arrives while the core business is growing at an unusual pace. In Q2 2026, Eli Lilly revenue rose 48% year on year to 22.97 billion USD, of which 14.87 billion USD came from Mounjaro and Zepbound. GAAP net income grew 25% to 7.10 billion USD, and adjusted earnings per share rose 33% to 8.38 USD.<\/p>\n\n
Mounjaro sales outside the United States grew especially fast and reached 5.2 billion USD, which shows Lilly can scale a GLP-1 drug across international markets. After the quarter, management raised 2026 revenue guidance from a range of 82 to 85 billion USD to a range of 85 to 87 billion USD.<\/p>\n\n
That gives Foundayo a comfortable starting position. Lilly can fund manufacturing, marketing and international promotion of the new pill out of the cash flow the existing line-up already generates, with no need for the launch to work immediately.<\/p>\n\n \n
<\/span>LLY Analyst Ratings<\/span><\/h2>\n\n
As of August 2026, Barchart analyst ratings<\/a> on Eli Lilly remain mostly positive. 26 of the 30 analysts covering the stock recommend buying it, and the remaining 4 say hold.<\/p>\n\n \n\n
\n\n
\n
\n
\n
\n
\n
26 out of 30<\/div>\n
recommend Buy (86%)<\/div>\n <\/div>\n
\n
Hold<\/div>
4 (14%)<\/div><\/div>\n
Sell<\/div>
0 (0%)<\/div><\/div>\n <\/div>\n
\n
Average Target Price<\/div>\n
1335.32 USD<\/div>\n <\/div>\n
\n
Maximum Target<\/div>
1600.00 USD<\/div><\/div>\n
Minimum Target<\/div>
850.00 USD<\/div><\/div>\n <\/div>\n <\/div>\n\n <\/div>\n\n
The average target price stands at 1335.32 USD, the highest at 1600.00 USD and the lowest at 850.00 USD. That spread shows a market that rates Lilly's prospects highly while staying careful about the current valuation and the dependence on further growth in GLP-1 sales.<\/p>\n\n \n
<\/span>LLY Stock: the Technical Picture<\/span><\/h2>\n\n
At the time of writing, LLY shares trade around 1245 USD.<\/p>\n\n
On the daily chart the price holds above the 200-period Moving Average<\/a> and above the 20- and 50-period Moving Averages, which points to an uptrend that is still intact. At the same time the Stochastic<\/a> indicator sits close to overbought territory, so further gains are likely to come with local pullbacks along the way. The stock is in an advancing phase, so entry risk here is higher than it would be after a decline.<\/p>\n\n
From that picture, the idea buys LLY at market price near 1245 USD. The target is 1400 USD, which lines up with the 161.80% Fibonacci level. The Stop Loss goes below support at 1140 USD, at the level of 1139 USD.<\/p>\n\n
$\"Eli$ <\/a>
Eli Lilly and Company (LLY) stock technical analysis and forecast, August 2026. Past results do not guarantee future performance.<\/figcaption><\/figure>\n\n
\n
The Moving Averages sit well below the current price,<\/strong> confirming the strength of the long-term uptrend.<\/li>\n
Stochastic is near overbought territory,<\/strong> pointing to pullbacks on the way toward the 1400 USD target.<\/li>\n
A market buy order<\/a><\/strong> is the best option here by risk and reward.<\/li>\n
The 161.80% Fibonacci level at 1400 USD<\/strong> is the reference point for this idea.<\/li>\n <\/ul>\n\n
Position management rule. Once the price has moved 8% in the direction of the forecast, the Stop Loss is moved up to the entry level. The protective order is then trailed behind the price at a distance of 8%. Management continues until the position closes at Take Profit or at Stop Loss, whichever the price reaches first.<\/p>\n\n \n
<\/span>Sample Trading Strategy for LLY Shares<\/span><\/h2>\n\n
Below is a sample trading strategy<\/a> for LLY shares. This example serves educational purposes only and does not constitute investment advice. Investors should assess their own risk tolerance independently.<\/p>\n\n
\n \n \n \n
Parameter<\/th> Value<\/th><\/tr>\n <\/thead>\n
Entry Point<\/td> Buy at market price around 1245.00 USD<\/strong><\/span><\/td><\/tr>\n
Take Profit<\/td> Fibonacci 161.80% at 1400.00 USD<\/strong><\/span><\/td><\/tr>\n
Stop Loss<\/td> 1139.00 USD<\/strong>, just below support at 1140 USD<\/span><\/td><\/tr>\n
Risk \/ Reward Ratio<\/td> 1 : 1.46, the potential profit is about 1.5 times the risk<\/span><\/td><\/tr>\n
Position Size<\/td> No more than 3% of account<\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n
Sample Calculation for 10 LLY Shares<\/h3>\n\n
\n \n \n \n \n \n \n \n
Scenario<\/th> Calculation<\/th> Result<\/th><\/tr>\n <\/thead>\n
Buy 10 shares at 1245.00 USD<\/td>\n 10 × 1245.00 USD<\/td>\n 12,450 USD<\/td>\n <\/tr>\n
If target reached (1400.00 USD)<\/td>\n (1400.00 − 1245.00) × 10<\/td>\n +1,550 USD (+12.4%)<\/td>\n <\/tr>\n
If stop triggered (1139.00 USD)<\/td>\n (1245.00 − 1139.00) × 10<\/td>\n −1,060 USD (−8.5%)<\/td>\n <\/tr>\n
Risk \/ Reward<\/strong><\/td>\n 1,060 \/ 1,550<\/td>\n 1 : 1.46<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n
A risk\/reward ratio of 1 : 1.46 is moderate. The potential profit only modestly exceeds the risk taken, which leaves little room for a sloppy entry. Markets are volatile, and LLY shares can move both for and against an open position.<\/p>\n\n
When This Idea Stops Being Valid<\/h3>\n\n
The idea rests on the daily uptrend holding. It stops being valid in three cases, and each one has a clear signal:<\/p>\n\n
\n
A daily close below 1139 USD.<\/strong> That takes the price under the support at 1140 USD, breaks the structure the entry was built on and triggers the stop. The position closes at a loss of about 8.5% of its value.<\/li>\n
A move above 1400 USD.<\/strong> The target is reached and the position closes in profit. Chasing the price beyond the Fibonacci 161.80% level is a different trade with different levels.<\/li>\n
Three months pass with no target.<\/strong> The horizon for this idea is one to three months. If the price is still stuck between the stop and the target at the end of that window, the reason for holding has expired and the position is reviewed from scratch.<\/li>\n <\/ul>\n\n
News can invalidate the idea before any of those levels arrive. A negative NICE decision on Foundayo, a fall in Foundayo prescriptions in the United States, or a Q3 report that misses on Mounjaro and Zepbound would all undercut the reasoning behind the entry, whatever the chart shows at that moment.<\/p>\n\n \n
\n
\n
Open an Account and Trade US Stocks<\/div>\n
Live charts, deposits and withdrawals, analytics and copy trading in one place.<\/div>\n <\/div>\n
\n Open an Account<\/a>\n <\/div>\n <\/div>\n\n \n
<\/span>Risks to Consider<\/span><\/h2>\n\n
Strong financial results and the Foundayo rollout sit alongside several real risks in the LLY investment case.<\/p>\n\n
\n
High investor expectations.<\/strong> The shares have already risen a long way, so further gains depend on the company holding a very high growth rate.<\/li>\n
Price pressure.<\/strong> In Q2 2026, Lilly's sales volume rose 60% while average realised prices fell 13%. Growth in patient numbers is arriving together with lower prices per treatment.<\/li>\n
Competition from Novo Nordisk.<\/strong> Oral Wegovy still holds an advantage in the tablet segment, and the market keeps getting more competitive.<\/li>\n
Limited access through public healthcare.<\/strong> Without positive decisions from regulators such as NICE, Foundayo may stay mainly a private prescription therapy.<\/li>\n
Side effects of GLP-1 drugs.<\/strong> Foundayo shares the gastrointestinal side effects typical of its class, and those can lead patients to stop treatment.<\/li>\n
Heavy dependence on diabetes and obesity drugs.<\/strong> Mounjaro and Zepbound together provide almost two thirds of company revenue, so any weakening of the GLP-1 market would show up quickly in Lilly's results.<\/li>\n <\/ul>\n\n
The central risk is the level of expectation already priced in. Good results on their own may be read as a disappointment, and Lilly has to keep beating what the market assumes.<\/p>\n\n \n
<\/span>Is Eli Lilly Stock Worth Buying on This News?<\/span><\/h2>\n\n
The UK launch of Foundayo is a positive development for Eli Lilly shares, because it gives the market another potential source of multi-year revenue growth. The significance lies in the start of international scaling for a new GLP-1 drug. British sales themselves will have limited effect on the financial results of the coming quarters.<\/p>\n\n
If Foundayo repeats even part of the Mounjaro and Zepbound trajectory, investors gain a reason to lift their expectations for future revenue and profit. That is the kind of shift that can drive a re-rating of LLY and support the share price from here.<\/p>\n\n
The first quarter of Foundayo sales in the United States came to 98 million USD. Mounjaro and Zepbound also started with modest volumes and now bring in billions of dollars per quarter. A rising prescription count, a more accessible price and the opening of international markets create the conditions for similar scaling.<\/p>\n\n
The strongest scenario for LLY combines continued growth in Mounjaro and Zepbound with accelerating Foundayo sales and entry into new markets. In that case the market can start pricing in a third multi-billion product. On the chart, the idea buys at market near 1245 USD, targets the Fibonacci 161.80% level at 1400 USD, and closes the position at 1139 USD if the support at 1140 USD gives way.<\/p>\n\n
\n Open a Trading Account with RoboForex<\/a>\n <\/div>\n\n
<\/span>FAQ<\/span><\/h2>\n\n
\n
\n
What is Foundayo?<\/summary>\n
Foundayo is Eli Lilly's oral GLP-1 drug for weight loss and type 2 diabetes control. It is taken once a day and does not require the food and water restrictions that come with oral Wegovy. It launched in the United States in April 2026 and in the United Kingdom in August 2026.<\/p>\n <\/details>\n
\n
Why does this trade idea target 1400 USD?<\/summary>\n
1400 USD lines up with the 161.80% Fibonacci extension of the recent uptrend, the level the technical picture points to from an entry near 1245 USD.<\/p>\n <\/details>\n
\n
What would invalidate this LLY trade idea?<\/summary>\n
A daily close below 1139 USD, since that breaks the support the entry rests on and triggers the stop. A negative NICE decision on Foundayo or a weak Q3 report from Mounjaro and Zepbound would undercut the reasoning even before the chart reaches that level.<\/p>\n <\/details>\n
\n
Does the Foundayo launch mean LLY shares will reach the target?<\/summary>\n
No. This is an educational trade idea built on the current technical and fundamental picture, not a promise of any specific price. LLY shares can move against the position, which is why the idea sets a stop-loss at 1139 USD.<\/p>\n <\/details>\n <\/div>\n\n
\n * Any information provided in articles on this website is based solely on the personal opinions of the authors. These articles should not be construed as trading recommendations or a call to action. The authors and RoboForex accept no responsibility for the results of any trades made on the basis of these recommendations and reviews. Past performance is not indicative of future results. Trading stocks and CFDs involves a high risk of capital loss.<\/em>\n <\/div>\n\n<\/div>\n<\/div>\n\n\n\n\n\n